Clinical Trials

Aclaris is committed to addressing the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. To learn more about our current clinical trials for our drug candidates, please visit:

Aclaris Therapeutics is committed to the discovery and development of medicines that will benefit people living with immuno-inflammatory diseases and cancer. Our investigational drugs are currently at a stage in development where we are focused on conducting clinical trials and continuing to learn more about their safety and efficacy.

At this time, our investigational drugs are only available for use in clinical trials and we are not accepting expanded access requests. We recognize the need for expanded access programs and will re-evaluate this policy when we have adequate data on efficacy, safety and dosing for patients with serious and life-threatening conditions who are not adequately treated with currently approved medicines and for whom there is no appropriate clinical study options. We may revise this policy at any time.

We encourage patients who are not adequately treated with currently approved medicines to consider if a clinical research study may be right for them. Information about our clinical trials is available at

Phase 2 trial of bosakitug (ATI-045) in moderate-to-severe atopic dermatitis (eczema)

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by skin barrier disruption and immune dysregulation. AD, also known as eczema, is a non-contagious skin condition that can range from mild to severe, and is often characterized by red, itchy, dry and cracked skin. Areas of the body that are commonly affected include the face, inside of the elbows, or behind the knees, but can appear anywhere on the body. During a flare, a common symptom is an itch, which can lead to an increased urge to scratch. The itching can be unbearable at times, and as the patient scratches, this can cause skin tears, bleeding blisters, pain, and changes in the natural color of the skin. People living with moderate-to-severe AD have a higher prevalence of social dysfunction and sleep impairment, which are typically directly related to the severity of the disease.

Phase 2 clinical trial

Aclaris has completed enrollment in a Phase 2 trial in subjects aged 18 to 70 years of age with moderate to severe atopic dermatitis (eczema).

For study details and information on our other clinical trials, visit clinicaltrials.gov